Novel immunological approaches in the treatment of Atopic eczema

Current Opinion in Allergy and Clinical Immunology

Volumn 8, Issue 5, 2008, Pages 423-427

  Belloni, Benedetta ^a   Andres, Christian ^a   Ollert, Markus ^a   Ring, Johannes ^a   Mempel, Martin ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Atopic eczema; Efalizumab; Leflunomide; Leukotriene receptor antagonists; Omalizumab; Rituximab; Sublingual immunotherapy; Tumor necrosis factor antagonists

Indexed keywords

ALANINE AMINOTRANSFERASE; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; EFALIZUMAB; EOTAXIN; ETANERCEPT; IMMUNOGLOBULIN E ANTIBODY; INFLIXIMAB; LEFLUNOMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONTELUKAST; OMALIZUMAB; PARACETAMOL; PEPTIDOLEUKOTRIENE; PRANLUKAST; PREDNISOLONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ZAFIRLUKAST;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CANCER RISK; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; FEVER; HEADACHE; HUMAN; IMMUNOTHERAPY; INFECTION; INJECTION SITE REACTION; LOADING DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PHARYNGITIS; PRIORITY JOURNAL; REMISSION; REVIEW; SIDE EFFECT; SKIN INFLAMMATION; T LYMPHOCYTE; TH2 CELL; THROMBOCYTOPENIA; TUBERCULOSIS;

ADULT; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DERMATITIS, ATOPIC; DESENSITIZATION, IMMUNOLOGIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; ISOXAZOLES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 53549121153     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32830fb8fd     Document Type: Review

References (46)

1. Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and knmunology/PRACTALL Consensus Report. Allergy 2006; 61:969-987.
2. Bieber T. Atopic dermatitis. N Engl J Med 2008; 358:1483-1494. An excellent review summarizing the recent findings in pathophysiology and therapy of atopic eczema.
3. Ring J, Przybilla B, Ruzicka T, Editors. Handbook of atopic eczema Berlin, Heidelberg, New York, Tokyo: Springer; 2005.
4. Novak N, Bieber T. The role of dendritic cell subtypes in the pathophysiology of atopic dermatitis. J Am Acad Demnatol 2005; 53:S171-S176.
5. Novak N, Bieber T, Leung DY. Immune mechanisms leading to atopic dermatitis. J Allergy din Immunol 2003; 112:S128-S139.
6. Leung DY, Jain N, Leo HL New concepts in the pathogenesis of atopic dermatitis. Curr Opin Immunol 2003; 15:634-638.
7. Weidinger S, O'Sullivan M, lllig T, ef al. Rlaggrin mutations, atopic eczema, hay fever, and asthma in children. J Allergy Clin Immunol 2008; 121: 1203.e1-1209.e1. An important extension of genetic factors underlying atopic eczema to other atopic diseases.
8. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common toss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38:441-446.
9. Pulvirenti N, Nasca MR, Micali G. Topical adeknidrol 2% emulsion, a novel aliamide, in the treatment of mild atopic dermatitis in pediatnc subjects: a pilot study. Acta Dermatovenerol Croat 2007; 15:80-83.
10. Kang JS, Youm JK, Jeong SK, et al. Topical application of a novel oeramide derivative, K6PC-9, inhibits dust mite extract-induced atopic dermatitis-like skin lesions in NC/Nga mice. Int Immunopharmacol 2007; 7:1589-1597.
11. Lebwohl M, Tyring S K, Hamilton T K, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349:2004-2013.
12. Saini R, Tutrone WD, Weinberg JM. Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus. Curr Pharm Des 2005; 11:273-280.
13. Hassan AS, Kaelin U, Braathen LR, Yawalkar N. Clinical and immunopathologic findings during treatment of recalcitrant atopic eczema with efalizumab. J Am Acad Dermatol 2007; 56:217-221. A good work-up of anti-CD 11a in atopic eczema.
14. Takiguchi R, Tofte S, Simpson B, et al. Efalizumab for severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 2007; 56:222-227.
15. Weinberg JM, Siegfried EC. Successful treatment of severe atopic dermatitis in a child and an adult with the T-cell modulator efalizumab. Arch Dermatol 2006; 142:555-558.
16. Gordon KB, Papp KA, Hamilton T K, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003; 290:3073-3080.
17. Menter A, Gordon K, Carey W, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005; 141:31-38.
18. Papp KA, Bressinck R, Fretzin S, et al. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase lllb, randomized, controlled trial. Int J Dermatol 2006; 45:605-614.
19. Scheinfeld N. Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin Drug Saf 2006; 5:197-209.
20. Lin J, Ziring D, Desai S, et al. TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008; 126:13-30.
21. Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanarysis of randomized controlled trials. J Rheumatol 2008; 35:883-890.
22. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117:244-279.
23. Cassano N, Loconsole F, Coviello C, Vena GA. Infliximab in recalcitrant severe atopic eczema associated with contact allergy. Int J Immunopathol Pharmacol 2006; 19:237-240.
24. Jacobi A, Antoni C, Manger B, et al. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2005; 52:522-526.
25. Chan JL, Davis-Reed L, Kimball AB. Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy. J Drugs Dermatol 2004; 3:315-318.
26. Wright RC. Atopic dermatitis-like eruption precipitated by infliximab. J Am Acad Dermatol 2003; 49:160-161.
27. Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2005; 53:338-340.
28. Vigo PG, Girgis KR, Pfuetze BL, et al. Efficacy of anti-lgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 2006; 55:168-170.
29. Belloni B, Ziai M, Lim A, et al. Low-dose anti-lgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007; 120:1223-1225. An extensive analysis of low-dose anti-lgE in high-serum IgE (slgE) atopic eczema patients.
30. Lim A, Luderschmidt S, Weidinger A, et al. The IgE repertoire in PBMCs of atopic patients is characterized by individual rearrangements without variable region of the heavy immunoglobulin chain bias. J Allergy Clin Immunol 2007; 120:696-706. Description of IgE and IgG mRNA changes as possible follow-up parameters of anti-lgE treatment in atopic eczema.
31. Lane JE, Cheyney JM, Lane TN, et al. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006; 54:68-72.
32. Deniz YM, Gupta N. Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-lgE antibody. Clin Rev Allergy Immunol 2005; 29:31-48.
33. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350:2572-2581.
34. Grillo-Lopez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody for the treatment of lymphoma. Semin Oncol 1999; 26:66-73.
35. Simon D, Hosli S, Kostylina G, et al. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008; 121:122-128. This study concludes very interesting results on B-cell depletion in atopic eczema with convincing clinical data.
36. Sediva A, Kayserova J, Vernerova E, et al. Anti-CD20 (rituximab) treatment for atopic eczema. J Allergy Clin Immunol 2008; 121:1515-1516. [author reply].
37. Ring J. Successful hyposensitization treatment in atopic eczema: results of a trial in monozygotic twins. Br J Dermatol 1982; 107:597-602.
38. Cadario G, Galluccio AG, Pezza M, et al. Sublingual immunotherapy efficacy in patients with atopic dermatitis and house dust mites sensitivity: a prospective pilot study. Curr Med Res Opin 2007; 23:2503-2506. An important study on sublingual immunotherapy with house dust mite extracts in atopic eczema.
39. Pajno GB, Caminiti L, Vita D, et al. Sublingual immunotherapy in mitesensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol 2007; 120:164-170. Evaluation of house dust mite sublingual immunotherapy in children by fulfilling high clinical study standards.
40. Bussmann C, Maintz L, Hart J, et al. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study. Clin Exp Allergy 2007; 37:1277-1285. Promising clinical and immunological results after specific immunotherapy (SIT) for house dust mites.
41. Werfel T, Breuer K, Rueff F, et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multicentre, randomized, dose-response study. Allergy 2006; 61:202-205.
42. Kehrer TBK, Wozel G. Eotaxin release is suppressed by the metabolite A 771726 of the novel immunomodulating agent leflunomide. Eur J Allergy Clin Immunol 2001; 56:144.
43. Wozel G, Vitez L, Pfeiffer C. Severe atopic dermatitis and leflunomide: first clinical experience and highlights of pertinent experimental data. Dermatol Online J 2006; 12:6.
44. Riccioni G, Bucciarelli T, Mancini B, et al. Antileukotriene drugs: clinical application, effectiveness and safety. Curr Med Chem 2007; 14:1966-1977.
45. Ehlayel MS, Bener A, Sabbah A. Montelukast treatment in children with moderately severe atopic dermatitis. Eur Ann Allergy Clin Immunol 2007; 39:232-236. An interesting study on the efficacy of montelukast in children with focus on atopic eczema.
46. Friedmann PS, Palmer R, Tan E, et al. A double-blind, placebo-controlled trial of montelukast in adult atopic eczema. Clin Exp Allergy 2007; 37:1536-1540. A very well carried out study for the use of montelukast in adults also focusing on atopic eczema.